FDA lifts OncoMed partial hold

The FDA lifted its partial clinical hold on OncoMed's anti-Fzd7 vantictumab last week. The drug was being tested among non-small cell lung cancer chemotherapy patients, as well as patients with advanced HER2-negative breast cancer or advanced pancreatic cancer. The FDA froze the clinical trial in July over concern about “bone-related adverse events.”

Jefferies analyst Thomas Wei wrote in a Thursday research note that OncoMed expects to modify dosing regimens and enrollment criteria.